12Mar 2023
Heart Failure Treatments and Outcomes in Obese Patients

Heart Failure Treatments and Outcomes in Obese Patients

This study aimed to investigate the use of guideline‐directed medical therapies (GDMT) and associated outcomes in obese (body mass index ≥30 kg/m2) versus non‐obese patients with heart failure (HF) with reduced ejection fraction (HFrEF). Obese patients were more likely to receive optimal treatments after adjustment for factors affecting tolerability, suggesting that perceived beyond actual tolerance issues limit GDMT implementation. RASi/ARNi and beta‐blockers were associated with lower mortality regardless of obesity. A more significant association between RASi/ARNi and lower cardiovascular death in obese versus non‐obese patients when considering competing risk.

  • #cardiology

Like

Save

Share